




Clinical Application of SPME: Analysis of VOCs in Exhaled Breath as Cancer Biomarkers



The following was generated with the assistance of an outside source using Sigma-Aldrich® products. Technical content was generated and provided by: **Bogusław Buszewski, Tomasz Ligor, Joanna Rudnicka** Department of Environmental Chemistry and Bioanalytics, Faculty of Chemistry Nicolaus Copernicus University, Gagarina 7 St., PL-87-100 Toruń, Poland

Introduction

Characteristic odors in breath have long been used as a tool for medical diagnosis. Familiar examples are diabetes with the odor of overripe apples, renal diseases with the fishy smell of amines and ammonia, and dental or liver diseases with the cabbage-like odor of organic sulfides¹. Linus Pauling applied formal science to the analysis by using gas chromatography (GC) to detect volatile organic compounds (VOC) in breath.² More recently, Michael Philips and his Menssana coworkers focused on determination of breath compounds that are attracting attention in clinical and toxicological analysis³. Although breath analysis is of great importance in disease detection, toxicology, and the study of metabolic processes, its use by doctors and clinicians as a diagnostic tool is a lost art.

The classes of VOCs that can be present in exhaled breath include hydrocarbons, alcohols, ketones, aldehydes, esters, and organic sulfides⁴. The determination of VOCs in exhaled air requires the detection of very low concentrations. Hence, the analytical methods employed must include a preconcentration step. The common preconcentration methodologies currently utilized for VOCs are sorption onto an adsorbent and cold trapping.

However, solid phase microextraction (SPME) is a viable alternative to these methods, as will be shown here. SPME has been widely used for the determination of volatile organic compounds in various matrices, including exhaled breath⁵. Compared to other preconcentration techniques, SPME is simple, inexpensive, and solvent-free. It is fully automatable, and no thermal desorption unit or modifications to the GC instrument are necessary. Compatible with all GC systems, SPME can be used by practically every laboratory. The objective of this study was to use SPME with GC-MS analysis to identify volatile biomarkers of lung cancer.

Experimental

Breath samples were collected from ten healthy volunteers and twelve patients with lung cancer. Each participant provided via questionnaire their age, sex, other diseases, medications, smoking habits, and composition of recent meals. Breath samples were collected in 1 L Tedlar® bags which were kept at a constant 25 °C. A gas standard containing the compounds of interest was made by vaporizing a liquid mixture of the compounds in a glass bulb.

A defined volume of the mixture was transferred into the Tedlar bag prior to sampling. During extraction, the CAR/PDMS SPME fiber was introduced into the bag containing breath sample or gas standards through a septum and exposed for 15 minutes. Ambient air samples were collected for background. External calibration was employed. The fiber desorption and sample analysis (GC-MS) conditions are shown in Figure 1.

Figure 1. GC-MS Analysis of VOC in Breath from Lung Cancer Patient after SPME Using CAR/PDMS Fibers

SPMF Conditions

sample: exhaled breath, 1 L in Tedlar bag

fiber: Carboxen®/Polydimethylsiloxane (CAR/PDMS), 75 µm film (57318)

holder: manual SPME holder (57330-U)

extraction: 15 min at 25 °C desorption: 1 min at 220 °C

GC-MS Conditions


column: GC PLOT column (Q-type), 25 m x 0.25 mm l.D., 3 μm

inj. temp.: 200 °C

oven: 40 °C (2 min), 10 °C/min to 140 °C, 5 °C/min to 270 °C (3 min)

carrier gas: helium, 40 cm/sec, constant injection: splitless 1 min, then split at 35:1

detector: MS, full scan, m/z 15-220, rate 3.46 scans/sec, El ion source and



Results

The linearity, precision, and detection limits for VOCs determination in human breath are presented in **Table 1**. The relative standard deviation (RSD) was in the range of 3.4% to 9.4%. Linear regression coefficient values (r^2) were close to 1. The lowest LOD values obtained for hydrocarbons varied from 0.3 to 0.49 ppb.



Table 1. Validation Parameters for Volatile Organic Compounds (VOCs)*

Compounds	Linear Range (ppb)	r ²	%RSD	LOD (ppb)	LOQ (ppb)
Acetone	1.6 - 920.7	0.991	8.9	0.54	1.62
Acetonitrile	2.3 - 234.0	0.996	3.4	0.75	2.25
Ethyl acetate	1.3 - 136.7	0.995	4.6	0.43	1.29
Methyl vinyl ketone	9.9 - 135.6	0.997	8.4	3.30	9.90
3-Methylpentane	1.3- 136.5	0.997	3.3	0.45	1.35
Ethanol	1.0 - 99.8	0.992	4.5	0.33	1.00
2-Methylfuran	1.6 - 165.6	0.999	4.9	0.54	1.63
2-Methylpentane	0.9 - 87.8	0.992	4.5	0.32	0.96
Hexanal	9.9 - 133.9	0.996	6.2	3.30	9.90
Hexane	1.5 - 150.0	0.994	3.4	0.49	1.47
Isoprene	2.6 - 380.2	0.998	3.7	0.87	2.62
Pentane	1.5 - 150.0	0.998	5.2	0.49	1.47
Methacrolein	11.7 - 170.4	0.998	7.2	3.91	11.73
1-Propanol	1.6 - 163.5	0.995	5.1	0.53	1.59
2-Propanol	1.6 - 159.6	0.998	9.4	0.52	1.57
Toluene	1.1 - 114.7	0.991	5.9	0.41	1.11
o-Xylene	1.0 - 100.1	0.994	4.8	0.33	0.99

^{*} Conditions same as Figure 1 except sample is a mixture of VOC standards. n=3. Bolded compounds had statistical significance.

Figure 1 shows a typical GC-MS chromatogram of breath from a lung cancer patient. Analysis of exhaled air from healthy volunteers and cancer patients identified seventeen volatile compounds, mainly hydrocarbons, ketones, aldehydes, and alcohols. Similar compounds were found in both healthy and cancer patients, except furan derivatives which are considered to be markers for tobacco smoking. Statistical tests were applied to distinguish cancer patients from the healthy control group. The VOC concentration data were log-transformed and tested for normality using the Shapiro-Wilks W test, (p<0.05). Full details of the statistical analysis is beyond the scope of this brief report; however, they are available upon request. Summarizing: Although there was variation between the patients and not all patients exhibited the same biomarker pattern, four compounds stood out statistically from the others: methyl vinyl ketone, 1-propanol, 2-propanol, and o-xylene. These compounds showed statistically higher levels in cancer patients compared to the healthy control group.

Conclusion

This brief report is intended to demonstrate the potential of solid phase microextraction (SPME) as a clinical research tool, in this case toward the extraction from human breath of VOCs associated with lung cancer. By using SPME with GC-MS analysis and applying rigorous statistical methods, we found the VOC profiles between a small set of healthy individuals and those diagnosed with lung cancer were significantly different. These promising findings would necessarily be followed up with studies on larger populations for definitive associations. The SPME-GC-MS method presented here had the requisite linearity and sensitivity, and could be easily adopted by laboratories as an investigational tool into biomarker discovery, among many other applications relevant to the clinical and biochemical fields.

Acknowledgments

This research work was supported by Grant N N 204 026238 (2010-2013).

References

- Risby T.H. Current status of clinical breath analysis. In *Breath Analysis for Clinical Diagnosis and Therapeutic Monitoring*; Amann, A., Smith, D., Eds.; World Scientific: Singapore, 2005.
- Pauling, L.; Robinson, A.B.; Teranishi R.; Cary P. Quantitative analysis of urine vapour and breath by gas-liquid partition chromatography. *Proc. Nat. Acad.* Sci. 1971, 68(10), 2374-2376.
- Phillips, M.; Gleeson, K.; Hughes, J.M.; Greenberg, J.; Cataneo, R.N.; Baker, L., McVay, W.P. Volatile organic compounds in breath as markers of lung cancer: a cross-sectional study. *Lancet*, **1999**, *353* (9168), 1930-1933.
- 4. Buszewski, B.; Kęsy, M.; Ligor, T.; Amann, A. Human exhaled air analytics: biomarkers of diseases. *Biomed. Chromatogr.* **2007**, *21*, 553-566.
- 5. Grote C.; Pawliszyn J. Solid phase microextraction for the analysis of human breath. *Anal. Chem.* **1997**, *69*, 587-596.



Featured Products

Description	Cat. No.
SPME fiber assembly Carboxen*/Polydimethylsiloxane (CAR/PDMS), needle size 24 ga, coating 75 μ m, for use with manual holder	57318
SPME fiber holder for use with manual sampling	57330-U
Capillary GC Column	
Supel-Q [™] PLOT, 30 m x 0.32 mm l.D.	24242
Standards	
For a complete listing of our volatile organic standards, visit sigma-aldrich.com/standards	

96-well plates are also available, but were not used in this study.

Enabling Science to Improve the Quality of Life Order/Customer Service (800) 325-3010 • Fax (800) 325-5052 Technical Service (800) 325-5832 • sigma-aldrich.com/techservice Development/Custom Manufacturing Inquiries **SAFC*** (800) 244-1173 Safety-related Information sigma-aldrich.com/safetycenter World Headquarters 3050 Spruce St. St. Louis, MO 63103 (314) 771-5765 sigma-aldrich.com

©2014 Sigma-Aldrich Co. LLC. All rights reserved. SIGMA-ALDRICH, ALDRICH and SUPELCO are trademarks of Sigma-Aldrich Co. LLC, registered in the US and other countries. Carboxen is a registered trademark of Sigma-Aldrich Co. LLC. Supel-0 is a trademark of Sigma-Aldrich Co. LLC. Tedlar is a registered trademark of E. I. du Pont de Nemours and Company. Supelco brand products are sold through Sigma-Aldrich, Inc. Purchaser must determine the suitability of the product(s) for their particular use. Additional terms and conditions may apply. Please see product information on the Sigma-Aldrich website at www.sigmaaldrich.com and/or on the reverse side of the invoice or packing slip.

QVQ 12090/T414076